The IMPROVE-2 trial is exploring a new way to treat metastatic colorectal cancer (mCRC) by comparing intermittent versus continuous use of Panitumumab plus chemotherapy (FOLFIRI) in patients with left-sided, RAS/BRAF wild-type mCRC. The goal is to maintain treatment effectiveness while reducing side effects and improving quality of life.

Current treatments can cause significant side effects and lead to drug resistance. This study will determine whether taking breaks from Panitumumab (intermittent treatment) is as effective as continuous use while improving tolerability. Researchers will also monitor blood samples over time to track tumour changes, detect resistance, and personalise future treatments.

A previous trial (IMPROVE-1) found intermittent treatment extended progression-free survival and reduced skin side effects compared to continuous treatment.

What does this mean to patients?

• Effective Treatment: Aims to show intermittent therapy works as well as continuous therapy.
• Fewer Side Effects: Reduces severe skin toxicity for better quality of life.
• Personalized Approach: Blood tests (liquid biopsies) will help track cancer changes for tailored treatments.

If successful, the IMPROVE-2 trial could change the standard approach for metastatic CRC, making treatment more manageable and effective for patients.

For more information about IMPROVE-1,  please click here.

Author:

Laura Urena